• 1
    Sreebny LM. Saliva in health and disease: an appraisal and update. Int Dent J 2000; 50: 140161.
  • 2
    von Bultzingslowen I, Sollecito TP, Fox PC et al. Salivary dysfunction associated with systemic diseases: systematic review and clinical management recommendations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103(Suppl): S57 e1–15.
  • 3
    Fox PC, Busch KA, Baum BJ. Subjective reports of xerostomia and objective measures of salivary gland performance. J Am Dent Assoc 1987; 115: 581584.
  • 4
    Pijpe J, Kalk WW, Bootsma H et al. Progression of salivary gland dysfunction in patients with Sjogren’s syndrome. Ann Rheum Dis 2007; 66: 107112.
  • 5
    Pedersen AM, Bardow A, Nauntofte B. Salivary changes and dental caries as potential oral markers of autoimmune salivary gland dysfunction in primary Sjogren’s syndrome. BMC Clin Pathol 2005; 5: 4.
  • 6
    Pajukoski H, Meurman JH, Halonen P et al. Prevalence of subjective dry mouth and burning mouth in hospitalized elderly patients and outpatients in relation to saliva, medication, and systemic diseases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92: 641649.
  • 7
    Orellana MF, Lagravere MO, Boychuk DG et al. Prevalence of xerostomia in population-based samples: a systematic review. J Public Health Dent 2006; 66: 152158.
  • 8
    Napeñas JJ, Brennan MT, Fox PC. Diagnosis and treatment of xerostomia (dry mouth). Odontology 2009; 97: 7683.
  • 9
    Brosky ME. The role of saliva in oral health: strategies for prevention and management of xerostomia. J Support Oncol 2007; 5: 215225.
  • 10
    Atkinson JC, Grisius M, Massey W. Salivary hypofunction and xerostomia: diagnosis and treatment. Dent Clin North Am 2005; 49: 309326.
  • 11
    Greenspan D. Xerostomia: diagnosis and management. Oncology (Williston Park) 1996; 10(Suppl 3): 711.
  • 12
    Gerdin EW, Einarson S, Jonsson M et al. Impact of dry mouth conditions on oral health-related quality of life in older people. Gerodontology 2005; 22: 219226.
  • 13
    Nieuw Amerongen AV, Veerman EC. Current therapies for xerostomia and salivary gland hypofunction associated with cancer therapies. Support Care Cancer 2003; 11: 226231.
  • 14
    Shiboski CH, Hodgson TA, Ship JA et al. Management of salivary hypofunction during and after radiotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103(Suppl): S66 e1–19.
  • 15
    Jensen SB, Pedersen AM, Vissink A et al. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact. Support Care Cancer 2010; 18: 10611079.
  • 16
    Turner MD, Ship JA. Dry mouth and its effects on the oral health of elderly people. J Am Dent Assoc 2007; 138(Suppl): 15S20S.
  • 17
    Silvestre FJ, Minguez MP, Sune-Negre JM. Clinical evaluation of a new artificial saliva in spray form for patients with dry mouth. Med Oral Patol Oral Cir Bucal 2009; 14: E8E11.
  • 18
    Ship JA, McCutcheon JA, Spivakovsky S et al. Safety and effectiveness of topical dry mouth products containing olive oil, betaine, and xylitol in reducing xerostomia for polypharmacy-induced dry mouth. J Oral Rehabil 2007; 34: 724732.
  • 19
    Momm F, Volegova-Neher NJ, Schulte-Monting J et al. Different saliva substitutes for treatment of xerostomia following radiotherapy. A prospective crossover study. Strahlenther Onkol 2005; 181: 231236.
  • 20
    McMillan AS, Tsang CS, Wong MC et al. Efficacy of a novel lubricating system in the management of radiotherapy-related xerostomia. Oral Oncol 2006; 42: 842848.
  • 21
    Alpoz E, Guneri P, Onder G et al. The efficacy of Xialine in patients with Sjogren’s syndrome: a single-blind, cross-over study. Clin Oral Investig 2008; 12: 165172.